# CLARITE 4- hydroquinone cream Vivier Pharma, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

## Clarite 4

## **Active Ingredient**

Hydroquinone USP (4%)

## Indication

Skin Bleaching and Correcting

## Indication

To gradually lighten hyperpigmentation of the skin such as age spots, liver spots, freckles or hyperpigmentation that can occur as a result of pregnancy or the use of oral contraceptives.

## **Precautions**

For external use only. Use only on the advice of a physician. A mild transient stinging may occur for people with sensitive skin. Do not use on broken or irritated skin. Discontinue use if irritation or rash occurs. Avoid contact with eyes and mucous membranes. In case of contact, rinse thoroughly with water. Do not use on children under 12 years of age. Keep out of reach of children. Avoid usage around the eyes and lips.

## **Precautions**

Keep out of reach of children.

## **Directions**

Use fingertips to apply a thin layer to affected areas. Use both morning and night or as directed by a physician. Gradual lightening of the discolored area can be expected in most cases. Close cap securely after each use. Store at room temperature (15-30°C / 59-86°F).

## **Non-Medicinal Ingredients**

Butylated Hydroxy Toluene, Butylparaben, Cetearyl Alcohol, Cetyl Alcohol, Disodium EDTA, Ethoxydiglycol, Fragrance/Parfum (Carubba C6929), Glycerin, Lactic Acid, L-Ascorbic Acid USP, Methylparaben, Phenyl Trimethicone, PPG-2 Myristyl Ether Propionate, Propylparaben, Sodium Cetearyl Sulfate, Sodium Lauryl Sulfate, Sodium Metabisulfite, Tocopheryl Acetate, Water/Eau.

## **Principal Display Panel**



## Clarite<sup>™</sup> 4

Crème d'Hydroquinone (4 %)

Crème éclaircissante et correctrice pour la peau

Seulement sur ordonnance<sup>†</sup>

60 mL 2 floz

#### INDICATION

NDC 67226-2040-6

To gradually lighten hyperpigmentation of the skin such as age spots, liver spots, freckles or hyperpigmentation that can occur as a result of pregnancy or the use of oral contraceptives.

#### DIRECTIONS

Use fingertips to apply a thin layer to affected areas. Use both morning and night or as directed by a physician. Gradual lightening of the discolored area can be expected in most cases. Close cap securely after each use. Store at room temperature (15-30°C / 59-86°F).

#### PRECAUTIONS

For external use only. Avoid contact with eyes. If contact occurs, rinse thoroughly with water. Keep out of reach of children. Use only on the advice of a physician. Contains Sodium Metabisulfite. See package insert for complete details.

ACTIVE INGREDIENT (w/w) Hydroquinone USP (4%)

NON-MEDICINAL INGREDIENTS INGRÉDIENTS NON-MÉDICINAUX Butylated Hydroxy Toluene, Butylparaben, Cetearyl Alcohol, Cetyl Alcohol, Disodium EDTA, Ethoxydiglycol, Fragrance/Parfum (Carubba C6929), Glycerin, Lactic Acid, L-Ascorbic Acid USP, Methylparaben, Phenyl Trimethicone, PPG-2 Myristyl Ether Propionate, Propylparaben, Sodium Cetearyl Sulfate, Sodium Lauryl Sulfate, Sodium Metabisulfite, Tocopheryl Acetate, Water/Eau.

t«Rx only» applies to USA





## Clarite<sup>™</sup> 4

Hydroquinone Cream (4%)

Skin Bleaching and Correcting Cream

Rx only

60 mL 2 floz

#### INDICATION

NDC 67226-2040-6

Pour l'éclaircissement graduel de l'hyperpigmentation de la peau telles les taches séniles. de vieillesse, de rousseur ou l'hyperpigmentation pouvant se manifester à la suite d'une grossesse ou de l'emploi de contraceptifs

#### MODE D'EMPLOI

En utilisant vos doigts, appliquer une mince couche sur la région affectée. Utiliser matin et soir ou selon l'avis d'un médecin. Avec une application continue, on peut constater un éclaircissement graduel de la peau, dans la plupart des cas. Bien visser le bouchon après chaque usage. Conserver à la température ambiante (15-30 °C / 59-86 °F).

#### **PRÉCAUTIONS**

Pour usage externe seulement. Éviter tout contact avec les yeux. En cas de contact, bien vous les rincer avec de l'eau. Garder hors de portée des enfants. Utiliser seulement selon les recommandations d'un médecin. Contient du métabisulfite de sodium. Pout tout renseignement, consulter l'info-feuillet

#### INGRÉDIENT ACTIF (p/p) Hydroguinone USP (4 %)

† « Seulement sur ordonnance » ne s'applique qu'aux É.-U.

Vivier Canada Inc. Mfd. for Vivier Pharma Hudson QC Canada JOP 11 Champlain NY USA 12919 Made in Canada 07-6105-35 vivierpharma.com



## **CLARITE 4**

hydroquinone cream

### **Product Information**

HUMAN OTC DRUG Product Type Item Code (Source) NDC:67226-2040

TOPICAL Route of Administration

## **Active Ingredient/Active Moiety**

**Basis of Strength Ingredient Name** Strength HYDRO Q UINO NE (UNII: XV74C1N1AE) (HYDRO Q UINO NE - UNII: XV74C1N1AE) HYDROQUINONE 4 g in 100 mL

## **Inactive Ingredients Ingredient Name** Strength BUTYLATED HYDRO XYTO LUENE (UNII: 1P9 D0 Z171K) BUTYLPARABEN (UNII: 3QPI1U3FV8)

CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)

CETYL ALCOHOL (UNII: 936JST6JCN)

EDETATE DISO DIUM (UNII: 7FLD9 1C86K)

DIETHYLENE GLYCOL MONOETHYL ETHER (UNII: A1A1I8 X02B)

GLYCERIN (UNII: PDC6A3C0OX)

LACTIC ACID (UNII: 33X04XA5AT)

ASCORBIC ACID (UNII: PQ6CK8PD0R)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PHENYL TRIMETHICO NE (UNII: DR0 K5NOJ4R)	
PPG-2 MYRISTYL ETHER PROPIONATE (UNII: 88R97D8U8A)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
SODIUM CETOSTEARYL SULFATE (UNII: 7ZBS06BH4B)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
SODIUM METABISULFITE (UNII: 4VON5FNS3C)	
.ALPHATO COPHEROL ACETATE (UNII: 9E8X80D2L0)	
WATER (UNII: 059QF0KO0R)	

Packaging				
# Item Code	Package Description	Marketing Start Date	Marketing End Date	
1 NDC:67226-2040-6	1 in 1 BOX			
1	60 mL in 1 TUBE			

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
OTC monograph not final	part358 A	05/30/2014			

# **Labeler** - Vivier Pharma, Inc. (250996550)

Establishment						
Name	Address	ID/FEI	Business Operations			
Vivier Pharma, Inc.		250996550	manufacture(67226-2040)			

Revised: 11/2013 Vivier Pharma, Inc.